Cargando…
Changes in the pharmacokinetic of sildenafil citrate in rats with Streptozotocin-induced diabetic nephropathy
AIM: The present investigates deals with the change in the pharmacokinetic of Sildenafil citrate (SIL) in disease condition like diabetic nephropathy (DN). METHOD: Diabetes was induced in rats by administering Streptozotocin i.e. STZ (60 mg/kg, IP) saline solution. Assessment of diabetes was done by...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922855/ https://www.ncbi.nlm.nih.gov/pubmed/24398037 http://dx.doi.org/10.1186/2251-6581-13-8 |
Sumario: | AIM: The present investigates deals with the change in the pharmacokinetic of Sildenafil citrate (SIL) in disease condition like diabetic nephropathy (DN). METHOD: Diabetes was induced in rats by administering Streptozotocin i.e. STZ (60 mg/kg, IP) saline solution. Assessment of diabetes was done by GOD-POD method and conformation of DN was done by assessing the level of Creatinine, Blood Urea Nitrogen (BUN) and Albuminurea. After the conformation of DN single dose of drug SIL (2.5 mg/kg, p.o.) were given orally and Pharmacokinetic Parameters like [AUC o-t (ug.h/ml), AUC 0-∞, C(max), T(max), Kel, Clast] were estimated in the plasma by the help of HPLC-UV. RESULT: There was significant increase (p < 0.01) in the Pharmacokinetic parameters of SIL in DN rat (AUC(0-t), AUC(0-∞), C(max), T(max) and T(1/2)) compare to normal control rat and significant increase Kel in the DN rat compare to control rat. CONCLUSION: The study concluded that there was significant (p < 0.01) increase in the bioavailability of SIL in DN. |
---|